Page 1878 - Hematology_ Basic Principles and Practice ( PDFDrive )

1668.e2 Part X Transplantation

50. Den Haan JM, Sherman NE, Blokland E, et al: Identification of a graft 73. Mullighan CG, Bardy PG: New directions in the genomics of allogeneic
versus host disease-associated human minor histocompatibility antigen. hematopoietic stem cell transplantation. Biol Blood Marrow Transplant
Science 268:1476, 1995. 13:127, 2007.
51. de Bueger M, Bakker A, Van Rood JJ, et al: Tissue distribution of 74. Cavet J, Dickinson AM, Norden J, et al: Interferon-gamma and
human minor histocompatibility antigens. Ubiquitous versus restricted interleukin-6 gene polymorphisms associate with graft-versus-host
tissue distribution indicates heterogeneity among human cytotoxic T disease in HLA-matched sibling bone marrow transplantation. Blood
lymphocyte-defined non-MHC antigens. J Immunol 149:1788, 1992. 98:1594, 2001.
52. de Bueger M, Goulmy E: Human minor histocompatibility antigens. 75. Holler E, Rogler G, Brenmoehl J, et al: Prognostic significance of
Transpl Immunol 1:28, 1993. NOD2/CARD15 variants in HLA-identical sibling hematopoietic
53. Goulmy E: Minor histocompatibility antigens: from transplantation stem cell transplantation: effect on long-term outcome is confirmed
problems to therapy of cancer. Hum Immunol 67:433, 2006. in two independent cohorts and may be modulated by the type of
54. Murata M, Warren EH, Riddell SR: A human minor histocompatibility gastrointestinal decontamination. Blood 107:4189, 2006.
antigen resulting from differential expression due to a gene deletion. J 76. Reddy P, Ferrara JL: Immunobiology of acute graft-versus-host disease.
Exp Med 197:1279, 2003. Blood Rev 17:187, 2003.
55. Malarkannan S, Shih PP, Eden PA, et al: The molecular and functional 77. Fefer A, Sullivan K, Weiden P: Graft versus leukemia effect in man:
characterization of a dominant minor H antigen, H60. J Immunol the relapse rate of acute leukemia is lower after allogeneic than after
161:3501, 1998. syngeneic marrow transplantation. In Truitt R, Gale R, Bortin M,
56. Bleakley M, Riddell SR: Molecules and mechanisms of the graft-versus- editors: Cell Immunother Cancer, New York, 1987, AR Liss, p 401.
leukaemia effect. Nat Rev Cancer 4:371, 2004. 78. Clift RA: Cellular support of the marrow transplant recipient. Prog Clin
57. Riddell SR, Bleakley M, Nishida T, et al: Adoptive transfer of allogeneic Biol Res 337:87, 1990.
antigen-specific T cells. Biol Blood Marrow Transplant 12:9, 2006. 79. Xun CQ, Thompson JS, Jennings CD, et al: Effect of total body
58. Choi EY, Christianson GJ, Yoshimura Y, et al: Real-time T-cell profiling irradiation, busulfan-cyclophosphamide, or cyclophosphamide condi-
identifies H60 as a major minor histocompatibility antigen in murine tioning on inflammatory cytokine release and development of acute
graft-versus-host disease. Blood 100:4259, 2002. and chronic graft-versus-host disease in H-2-incompatible transplanted
59. Choi EY, Christianson GJ, Yoshimura Y, et al: Immunodominance of SCID mice. Blood 83:2360, 1994.
H60 is caused by an abnormally high precursor T cell pool directed 80. Cooke KR, Hill GR, Gerbitz A, et al: Tumor necrosis factor-alpha
against its unique minor histocompatibility antigen peptide. Immunity neutralization reduces lung injury after experimental allogeneic bone
17:593, 2002. marrow transplantation. Transplantation 70:272, 2000.
60. Fontaine P, Roy-Proulx G, Knafo L, et al: Adoptive transfer of minor 81. Abu JI, Habiba MA, Baker R, et al: Quantitative and qualitative
histocompatibility antigen-specific T lymphocytes eradicates leukemia assessment of women’s experience of a one-stop menstrual clinic in
cells without causing graft-versus-host disease. Nat Med 7:789, 2001. comparison with traditional gynaecology clinics. BJOG 108:993,
61. Dickinson AM, Wang XN, Sviland L, et al: In situ dissection of the 2001.
graft-versus-host activities of cytotoxic T cells specific for minor histo- 82. Hempel L, Korholz D, Nussbaum P, et al: High interleukin-10 serum
compatibility antigens. Nat Med 8:410, 2002. levels are associated with fatal outcome in patients after bone marrow
62. de Bueger M, Bakker A, Bontkes H, et al: High frequencies of cytotoxic transplantation. Bone Marrow Transplant 20:365, 1997.
T cell precursors against minor histocompatibility antigens after HLA- 83. Tawara I, Koyama M, Liu C, et al: Interleukin-6 modulates graft-
identical BMT: absence of correlation with GVHD. Bone Marrow versus-host responses after experimental allogeneic bone marrow
Transplant 11:363, 1993. transplantation. Clin Cancer Res 17(1):77–88, 2011.
63. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al: Successful adoptive 84. Matzinger P: The danger model: a renewed sense of self. Science
transfer and in vivo expansion of human haploidentical NK cells in 296:301, 2002.
patients with cancer. Blood 105:3051, 2005. 85. Shlomchik WD, Couzens MS, Tang CB, et al: Prevention of graft
64. Miller JS, Cooley S, Parham P, et al: Missing KIR-ligands is associated versus host disease by inactivation of host antigen-presenting cells.
with less relapse and increased graft versus host disease (GVHD) fol- Science 285:412, 1999.
lowing unrelated donor allogeneic HCT. Blood 109:5058, 2007. 86. Murai M, Yoneyama H, Ezaki T, et al: Peyer’s patch is the essential site
65. Velardi A, Ruggeri L, Moretta A, et al: NK cells: a lesson from mis- in initiating murine acute and lethal graft-versus-host reaction. Nat
matched hematopoietic transplantation. Trends Immunol 23:438, 2002. Immunol 4:154, 2003.
66. Hsu KC, Gooley T, Malkki M, et al: KIR ligands and prediction 87. Choi SW, Islam S, Greenson JK, et al: The use of laparoscopic liver
of relapse after unrelated donor hematopoietic cell transplantation biopsies in pediatric patients with hepatic dysfunction following allo-
for hematologic malignancy. Biol Blood Marrow Transplant 12:828, geneic hematopoietic stem cell transplantation. Bone Marrow Transplant
2006. 36:891, 2005.
67. Ruggeri L, Capanni M, Urbani E, et al: Effectiveness of donor natural 88. Champlin RE, Passweg JR, Zhang MMJ, et al: T-cell depletion of bone
killer cell alloreactivity in mismatched hematopoietic transplants. marrow transplants for leukemia from donors other than HLA-identical
Science 295:2097, 2002. siblings: advantage of T-cell antibodies with narrow specificities. Blood
68. Davies SM, Ruggieri L, DeFor T, et al: Evaluation of KIR ligand incom- 95:3996, 2000.
patibility in mismatched unrelated donor hematopoietic transplants. 89. Clouthier SG, Ferrara JL, Teshima T: Graft-versus-host disease in the
Killer immunoglobulin-like receptor. Blood 100:3825, 2002. absence of the spleen after allogeneic bone marrow transplantation.
69. Hsu KC, Keever-Taylor CA, Wilton A, et al: Improved outcome in Transplantation 73:1679, 2002.
HLA-identical sibling hematopoietic stem-cell transplantation for acute 90. Jones SC, Murphy GF, Friedman TM, et al: Importance of minor
myelogenous leukemia predicted by KIR and HLA genotypes. Blood histocompatibility antigen expression by nonhematopoietic tissues in
+
105:4878, 2005. a CD4 T cell-mediated graft-versus-host disease model. J Clin Invest
70. Cavet J, Middleton PG, Segall M, et al: Recipient tumor necrosis 112:1880, 2003.
factor-alpha and interleukin-10 gene polymorphisms associate 91. Reddy P, Maeda Y, Liu C, et al: A crucial role for antigen-presenting
with early mortality and acute graft-versus-host disease severity cells and alloantigen expression in graft-versus-leukemia responses. Nat
in HLA-matched sibling bone marrow transplants. Blood 94:3941, Med 11:1244, 2005.
1999. 92. Arpinati M, Green CL, Heimfeld S, et al: Granulocyte-colony stimulat-
71. Dickinson AM, Charron D: Non-HLA immunogenetics in hematopoi- ing factor mobilizes T helper 2-inducing dendritic cells. Blood 95:2484,
etic stem cell transplantation. Curr Opin Immunol 17:517, 2005. 2000.
72. Lin MT, Storer B, Martin PJ, et al: Relation of an interleukin-10 93. Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, et al: Rapid estab-
promoter polymorphism to graft-versus-host disease and survival after lishment of dendritic cell chimerism in allogeneic hematopoietic cell
hematopoietic-cell transplantation. N Engl J Med 349:2201, 2003. transplant recipients. Blood 99:1442, 2002.